Literature DB >> 29111007

Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.

D Langeskov-Christensen1, P Feys2, I Baert2, M Riemenschneider1, E Stenager3, U Dalgas4.   

Abstract

BACKGROUND: The severity of walking impairment in persons with multiple sclerosis (pwMS) at different levels on the expanded disability status scale (EDSS) is unclear. Furthermore, it is unclear if the EDSS is differently related to performed- and perceived walking capacity tests. AIMS: To quantify walking impairment and perceived impact of MS on walking according to EDSS scores and to examine the relations between these parameters in pwMS.
METHODS: EDSS was collected by neurologists and walking was assessed by the timed 25ft walk test (T25FWT), two minute walk test (2MWT), six minute walk test (6MWT) and the 12-item MS walking scale (MSWS-12) in 474 PwMS with mild (EDSS 1-4: n=200) to moderate (EDSS 4.5-6.5: n=274) MS. Magnitude of walking impairment was calculated and related to EDSS.
RESULTS: Compared to predicted values in healthy controls, walking speed was reduced by 41.5±25.8% in the 6MWT for the total MS group and by 21.8±20.2% and 55.8±19.1% in the mild and moderate MS subgroups, respectively. The EDSS score showed the strongest relationship to the 2MWT and the 6MWT in the total MS group (r=-0.76, p<0.0001), to the MSWS-12 score in the mild MS group (r=0.56, p<0.0001), and to the 2MWT in the moderate MS group (r=-0.50, p<0.0001).
CONCLUSION: In pwMS (EDSS scores 1-6.5), walking speed is on average reduced by ~40% when compared to predicted values in healthy controls, and impairments are already present at early disease stages, suggesting early initiation of rehabilitation. The 2MWT and 6MWT show the strongest relationship to EDSS, but the MSWS-12 identify impairments more gradually at low EDSS scores.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6MWT; EDSS; MSWS-12; Multiple sclerosis; Walking impairment; Walking measures

Mesh:

Year:  2017        PMID: 29111007     DOI: 10.1016/j.jns.2017.09.049

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE.

Authors:  Raymond Hupperts; Claudio Gasperini; Jan Lycke; Tjalf Ziemssen; Peter Feys; Shan Xiao; Carlos Acosta; Thijs Koster; Jeremy Hobart
Journal:  Ther Adv Neurol Disord       Date:  2022-05-18       Impact factor: 6.430

2.  Two-minute walk test: Reference equations for healthy adults in China.

Authors:  Jia Zhang; Xiaoshu Chen; Shiwei Huang; Yi Wang; Wei Lin; Rui Zhou; He Zou
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

3.  Study protocol: randomised controlled trial evaluating exercise therapy as a supplemental treatment strategy in early multiple sclerosis: the Early Multiple Sclerosis Exercise Study (EMSES).

Authors:  Morten Riemenschneider; Lars G Hvid; Steffen Ringgaard; Mikkel K E Nygaard; Simon F Eskildsen; Thor Petersen; Egon Stenager; Ulrik Dalgas
Journal:  BMJ Open       Date:  2021-01-12       Impact factor: 2.692

4.  Balance Right in Multiple Sclerosis (BRiMS): a feasibility randomised controlled trial of a falls prevention programme.

Authors:  H Gunn; K N Stevens; S Creanor; J Andrade; L Paul; L Miller; C Green; P Ewings; A Barton; M Berrow; J Vickery; B Marshall; J Zajicek; J A Freeman
Journal:  Pilot Feasibility Stud       Date:  2021-01-04

5.  Longitudinal relationships between disability and gait characteristics in people with MS.

Authors:  Sapir Dreyer-Alster; Shay Menascu; Mark Dolev; Uri Givon; David Magalashvili; Anat Achiron; Alon Kalron
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

Review 6.  Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Authors:  Philipp Albrecht; Ingrid Kristine Bjørnå; David Brassat; Rachel Farrell; Peter Feys; Jeremy Hobart; Raymond Hupperts; Michael Linnebank; Jožef Magdič; Celia Oreja-Guevara; Carlo Pozzilli; Antonio Vasco Salgado; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2018-10-05       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.